Cellergy Pharma

Cellergy Pharma is an innovative, private biotech leveraging CAR T cell technology to address severe allergic diseases, a novel and significant expansion of this therapeutic modality. The company is in the pre-clinical or early research stage, focusing on large, underserved markets such as severe allergic asthma and food allergies. As a pre-revenue entity, its success hinges on validating its platform in non-oncological settings, securing substantial funding, and navigating the complex regulatory pathway for a first-in-class cell therapy in allergy.

CAR T cell platform engineered to target and eliminate IgE-producing B-lineage cells for the treatment of severe allergic diseases.

Cellergy's approach is highly novel, with no direct CAR T competitors in allergy. However, it competes indirectly with established biologic drugs (e.g., anti-IgE, anti-IL-5) for asthma and emerging oral immunotherapies for food allergy. Other disruptive modalities, like bispecific antibodies or gene editing, are also in early research for similar indications.